Controlled release formulations of octreotide

Details Controlled release formulations of octreotide Controlled release formulations of octreotide

2006-03-10

2008-11-18

Tsang, Cecilia (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C424S422000, C424S461000, C424S462000, C526S329700

Reexamination Certificate

active

07452868

ABSTRACT:
A formulation of octreotide or pharmaceutically acceptable salts thereof, which provides controlled release of a therapeutically effective amount of octreotide for a period of at least about two months. Methods of treating acromegaly, decreasing growth hormone, decreasing IGF-1, and treating conditions associated with carcinoid tumors and VIPomas by administering a controlled release formulation of octreotide are provided herein.

REFERENCES:
patent: 4131604 (1978-12-01), Szycher
patent: 4386039 (1983-05-01), Szycher
patent: 4523005 (1985-06-01), Szycher
patent: 4743673 (1988-05-01), Johnston et al.
patent: 4751133 (1988-06-01), Szycher et al.
patent: 5254662 (1993-10-01), Szycher et al.
patent: 5266325 (1993-11-01), Kuzma et al.
patent: 5292515 (1994-03-01), Moro et al.
patent: 5342622 (1994-08-01), Williams et al.
patent: 5354835 (1994-10-01), Blair
patent: 5468811 (1995-11-01), Moro et al.
patent: 5614223 (1997-03-01), Sipos
patent: 5876761 (1999-03-01), Bodmer et al.
patent: 6313254 (2001-11-01), Meijs et al.
patent: 6361797 (2002-03-01), Kuzma et al.
patent: 2005/0037078 (2005-02-01), Kuo et al.
RxMed: Pharmaceutical Information-Sandostatin LAR Depot [online], Jan. 6, 2003 [retrieved Aug. 16, 2006]. Retrieved from the internet: <URL:http://www.rxmed.com>.
Higuchi et al., Pro-drugs as Novel Delivery Systems, 1975, vol. 14 ACS Symposium Series.
Higuchi et al., Pro-drugs as Novel Delivery Systems, 1987, Bioreversible Carriers in Drug Design, Edward B. Roche ed., Amer. Pharmaceutical Assoc. and Pergamon Press, 1987.
Berge et al. Pharmaceutical Salts, 1977, J. Pharm. Sci., 66(1):1-19.
Bevan et al., Primary Medical Therapy for Acromegaly: An Open, Prospective, Multicenter Study of the Effects of Subcutaneous and Intramuscular Slow-Release Octreotide on Growth Hormone, Insulin-Like Growth Factor-L, and Tumor Size, 2002, J. Clin. Endoc. Metab. 87(10):4554-4563.

Affiliated with

Also associated with

Rating

Controlled release formulations of octreotide does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Controlled release formulations of octreotide, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Controlled release formulations of octreotide will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4034699